Health Technology Assessment Review: Exploring Consultation 2

By HEOR Staff Writer

February 12, 2024

Introduction:

The Office of Health Technology Assessment Review has launched the second consultation of the Health Technology Assessment (HTA) Review, a crucial step towards improving Australia’s HTA policies and methods. This article is based on the latest HTA Review updates published early in February 2024 by the Pharmaceutical Benefits Advisory Committee (PBAC).

The Purpose and Goals of Consultation 2

The HTA Review’s Consultation 2 is a significant part of the Strategic Agreement, aimed at ensuring Australia’s assessment processes stay abreast with rapid advances in health technology. The consultation seeks to understand potential implications and identify unintended outcomes of the proposed options for reform.

The Role of the HTA Review Reference Committee

The HTA Review Reference Committee, announced by the Minister for Health in October 2022, oversees the HTA Review. The Committee plays a crucial role in developing the options paper and considering feedback from various stakeholders before finalising recommendations.

Participating in Consultation 2

Stakeholders are invited to participate through an online survey or attend workshops, either in-person or online. The consultation period is open until the end of February 2024, with workshops scheduled throughout the month.

The Scope and Impact of Consultation 2

The consultation welcomes feedback on the Options Paper in relation to the proposed HTA review scope. The outcomes of this consultation could shape the future of HTA policies and methods, potentially impacting stakeholders across the healthcare industry.

Conclusion:

The HTA Review’s Consultation 2 is a crucial step towards improving Australia’s health technology assessment processes. The feedback and insights gained from this process will undoubtedly shape the future of healthcare in the country.

Reference url

Recent Posts

Fabhalta Kidney Treatment Shows Promise in Slowing Disease Progression for IgA Nephropathy

By João L. Carapinha

October 21, 2025

Novartis has announced positive final results from the Phase III APPLAUSE-IgAN trial, which demonstrated that Fabhalta kidney treatment (iptacopan) achieved a statistically significant and clinically meaningful slowing of kidney function decline in patients with IgA nephropathy compared to placeb...
Cabotegravir HIV Prevention: First Injectable PrEP Recommended for High-Risk Groups

By HEOR Staff Writer

October 17, 2025

Cabotegravir HIV prevention is now officially recommended in the UK for adults and young people at high risk of HIV who cannot take daily oral PrEP. What makes this approval so significant? For those unable to adhere to daily medication, cabotegravir provides a bi-monthly injectable alternative w...
Tukysa Breast Cancer Therapy Boosts Progression-Free Survival in Advanced Cases

By João L. Carapinha

October 15, 2025

Tukysa breast cancer therapy, developed by Pfizer, has shown remarkable efficacy in improving progression-free survival (PFS) for patients with HER2-positive metastatic breast cancer. Recent findings indicate that the combination of Tukysa (tucatinib) with trastuzumab and capecitabine significant...